+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Olaparib"

Prostate Cancer Drugs Market Report 2026 - Product Thumbnail Image

Prostate Cancer Drugs Market Report 2026

  • Report
  • February 2026
  • 250 Pages
  • Global
From
From
Ovarian Cancer Drugs - Global Strategic Business Report - Product Thumbnail Image

Ovarian Cancer Drugs - Global Strategic Business Report

  • Report
  • August 2026
  • 326 Pages
  • Global
From
Prostate Cancer Therapeutics - Global Strategic Business Report - Product Thumbnail Image

Prostate Cancer Therapeutics - Global Strategic Business Report

  • Report
  • August 2026
  • 217 Pages
  • Global
From
From
From
Ovarian Cancer Drugs Market - Product Thumbnail Image

Ovarian Cancer Drugs Market

  • Report
  • September 2025
  • 150 Pages
  • Global
From
Prostate Cancer Therapeutics Market - Product Thumbnail Image

Prostate Cancer Therapeutics Market

  • Report
  • September 2025
  • 150 Pages
  • Global
From
From
Olaparib Tablets Market - Global Forecast 2025-2030 - Product Thumbnail Image

Olaparib Tablets Market - Global Forecast 2025-2030

  • Report
  • August 2025
  • 199 Pages
  • Global
From
Olaparib API Market - Global Forecast 2025-2030 - Product Thumbnail Image

Olaparib API Market - Global Forecast 2025-2030

  • Report
  • August 2025
  • 182 Pages
  • Global
From
From
LYNPARZA Market Drug Insight and Market Forecast - 2032 - Product Thumbnail Image

LYNPARZA Market Drug Insight and Market Forecast - 2032

  • Report
  • February 2023
  • 30 Pages
  • Global
From
United States LYNPARZA Drug Insight and Market Forecast - 2032 - Product Thumbnail Image

United States LYNPARZA Drug Insight and Market Forecast - 2032

  • Drug Pipelines
  • January 2023
  • 30 Pages
  • United States
From
Olaparib + bevacizumab Emerging Drug Insight and Market Forecast - 2032 - Product Thumbnail Image

Olaparib + bevacizumab Emerging Drug Insight and Market Forecast - 2032

  • Drug Pipelines
  • December 2022
  • 30 Pages
  • Global
From
Ovarian Cancer Drug Pipeline Analysis Report 2025 - Product Thumbnail Image

Ovarian Cancer Drug Pipeline Analysis Report 2025

  • Drug Pipelines
  • June 2025
  • 200 Pages
  • Global
From
Advanced Ovarian Cancer Drug Pipeline Analysis Report 2025 - Product Thumbnail Image

Advanced Ovarian Cancer Drug Pipeline Analysis Report 2025

  • Drug Pipelines
  • June 2025
  • 200 Pages
  • Global
From
Metastatic Prostate Cancer Drug Pipeline Analysis Report 2025 - Product Thumbnail Image

Metastatic Prostate Cancer Drug Pipeline Analysis Report 2025

  • Drug Pipelines
  • June 2025
  • 200 Pages
  • Global
From
Loading Indicator

Olaparib is a type of breast cancer drug used to treat advanced breast cancer in women with certain genetic mutations. It is a poly ADP-ribose polymerase (PARP) inhibitor, which works by blocking the action of an enzyme that helps cancer cells repair themselves. This makes it harder for the cancer cells to survive and grow. Olaparib is used in combination with other treatments, such as chemotherapy, to help slow the growth of cancer cells. It is also used to treat metastatic breast cancer, which is cancer that has spread to other parts of the body. Olaparib is approved by the US Food and Drug Administration (FDA) for the treatment of advanced breast cancer in women with certain genetic mutations. It is also approved in the European Union and other countries. Some companies in the Olaparib market include AstraZeneca, Merck, Pfizer, and GlaxoSmithKline. These companies are involved in the research, development, and marketing of Olaparib and other breast cancer drugs. Show Less Read more